Last updated on September 2016

Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer


Brief description of study

Objectives: To evaluate the safety and effectiveness of cell therapy using Precision Cell Immunotherapy to treat Advanced Gastric Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Gastric Cancer.

Detailed Study Description

A total of 40 patients may be enrolled over a period of 1-2 years.

Clinical Study Identifier: NCT02862561

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Naiyan Han

Shanghai International Medical Center
Shanghai, China
  Connect »